REVELATION BIOSCIENCES, INC.
Datakwaliteit: 83%
€ 1,17
▼
€ 0,06
(-4,88%)
Marktkapitalisatie: 4,58 M
Prijs
€ 1,23
Marktkapitalisatie
4,58 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
Negative free cash flow of -8,29 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-120,23%
Onder sectorgemiddelde (-53,34%)
ROIC-96,66%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio6,92
Interest CoverageN/A
Waardering
PE (TTM)
-0,51
Boven sectorgemiddelde (-1,47)
P/B Ratio0,42
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -0,5 | -1,5 |
| P/B | 0,4 | 1,6 |
| ROE % | -120,2 | -53,3 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -8,91 M |
| ROE | -120,23% | ROA | -97,68% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -8,29 M |
| ROIC | -96,66% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 6,92 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 10,98 M | Tangible Book Value | 11,00 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,51 | Forward P/E | N/A |
| P/B Ratio | 0,42 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -181,13% | ||
| Market Cap | 4,58 M | Enterprise Value | -8,13 M |
| Per Share | |||
| EPS (Diluted TTM) | -23,95 | Revenue / Share | N/A |
| FCF / Share | -2,23 | OCF / Share | -2,22 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 92,99% |
| SBC-Adj. FCF | -8,55 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -8,91 M | -15,04 M | -120.254,0 | -10,83 M | -2,13 M |
| EPS (Diluted) | -23,95 | -87,68 | -0,53 | -20,09 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -9,07 M | -7,98 M | -8,66 M | -10,86 M | — |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 4,06 M | 3,55 M | 4,15 M | 5,38 M | — |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | — | — | 41.759,0 |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 11,58 M | 6,62 M | 12,21 M | 5,50 M | 48,39 M |
| Total Liabilities | 2,72 M | 1,91 M | 5,56 M | 4,45 M | 8,40 M |
| Shareholders' Equity | 8,86 M | 4,71 M | 6,65 M | 1,05 M | -7,82 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 10,70 M | 6,50 M | 11,99 M | 5,25 M | 78.532,0 |
| Current Assets | 10,81 M | 6,57 M | 12,15 M | 5,41 M | 83.366,0 |
| Current Liabilities | 2,00 M | 1,91 M | 5,56 M | 4,45 M | 5,49 M |
{"event":"ticker_viewed","properties":{"ticker":"REVB","listing_kind":"stock","pathname":"/stocks/revb","exchange":"Nasdaq","country":"US"}}